Amato J. Giaccia

Honors and Awards

• MERIT Award, NIH (2010)
• Jack, Lulu and Sam Willson Endowed Professor of Cancer Biology, Stanford University (2006)
• Virginia Logan Lecture, Thomas Jefferson University (2003)
• John Yuhas Award (Excellence in Radiation Oncology, University of Pennsylvania), University of Pennsylvania (2000)
• Michael Fry Research Awardee of the Radiation Research Society, Radiation Research Society (1997)

Postdoctoral Advisees

Laura Castellini,  Elizabeth Finger,  Katherine Fuh,  Edward LaGory,  Yu Miao,  Eui Jung Moon,  Erinn Rankin,  Olga Razorenova,  Cullen Taniguchi,  Kartik Viswanathan,  Colleen Wu

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information

Current Research Interests

During the last five years, we have identified several small molecules that acted to kill VHL deficient renal cancer cells through a synthetic lethal screening approach. We published on one of the molecules (Cancer Cell 14: 90, 2008) that killed VHL deficient tumor and are performing screens to identify new therapeutics against other targets. Another major interest of my laboratory is in identifying hypoxia-induced genes involved in invasion and metastases. We have identified and characterized several genes that are induced by hypoxia and promote metastases in breast, ovarian, renal and head and neck cancer (Nature 440:1222, 2006, Cancer Cell 15:35, 2009) and are developing therapeutics against them. My group is also investigating how hypoxia regulates gene expression epigenetically through the regulation of histone demethylases and microRNAs.

Clinical Trials

• Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers Recruiting

Publications

• Global alteration in gene expression profiles of deciduas from women with idiopathic recurrent pregnancy loss. Krieg SA, Fan X, Hong Y, Sang QX, Giaccia A, Westphal LM, Lathi RB, Krieg AJ, Nayak NR. Mol Hum Reprod. 2012
• Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, O''Sullivan B, Giaccia A, Rischin D. Clin Cancer Res. 2012
• The HIF Signaling Pathway in Osteoblasts Directly Modulates Erythropoiesis through the Production of EPO. Rankin EB, Wu C, Khatri R, Wilson TL, Andersen R, Araldi E, Rankin AL, Yuan J, Kuo CJ, Schipani E, Giaccia AJ. Cell. 2012; 149 (1): 63-74
• A central role for hypoxic signaling in cartilage, bone, and hematopoiesis. Rankin EB, Giaccia AJ, Schipani E. Curr Osteoporos Rep. 2011; 9 (2): 46-52
• Basic Principles of Radiobiology Horst KC, Giaccia AJ. Breast Surgical Techniques and Interdisciplinary Management. 2011: 799-812